急性心肌梗死溶栓疗法临床分析

目的 分析溶栓疗法治疗急性心肌梗死的疗效.方法 选择发病在12h内的急性心肌梗死患者30例,在对症治疗的同时立即给予静脉滴注尿激酶100万U,分析患者的冠状动脉再通率情况.结果 30例患者中26例再通,再通率为86.67%,没有发生严重的不良反应.结论 心肌梗死后早期采用静滴尿激酶进行溶栓安全、有效,值得临床推广应用.     

冠状动脉造影评价急性心肌梗死溶栓疗法的疗效

目的：冠状动脉造影（ＣＡＧ）评价静脉溶栓治疗急性心肌梗死（ＡＭＩ）的疗效及安全性。方法：１１０例ＡＭＩ患者应用国产尿激酶及进口链激酶开始溶栓治疗后９０分钟行ＣＡＧ。结果：尿激酶和链激酶血管开通率分别为６０．８％及６３．０％；ＣＡＧ提示有残留血栓的分别为８６．９％及８１．５％；５周病死率分别为８．６％及７．４％；严重出血并发症分别为１．８５％及２．１７％，均无统计学意义。加大尿激酶剂量至２００ＩＵ，并不增加血管开通率反而增加出血并发症。结论：ＡＭＩ是由突然冠状动脉血栓性闭塞所致。尿激酶和链激酶用于静脉溶栓治疗可使闭塞的冠状动脉再通，两种溶栓剂疗效相似     

基于改良德尔菲法对急性心肌梗死中医诊疗方案的调查分析

目的运用改良德尔菲法进行专家咨询,探讨急性心肌梗死(AMI)再灌注治疗后中医优化诊疗方案。方法在文献调研基础上,对全国中医、中西医结合心血管病专家进行两轮咨询调查,从AMI辨证分型、治法、治疗方案等方面进行咨询。结果共发出问卷20份,收回20份,专家积极系数为100%;AMI的基本证候要素选择频次排列如下:血瘀气虚痰浊阴虚阳虚寒凝气滞。辨证治疗方面选择频次排列如下:气虚血瘀气虚痰瘀痰浊痹阻瘀血闭阻寒凝心脉气阴两虚心阳不振。再灌注治疗后,中医主要治法的选择依次为活血益气化痰温阳养阴祛寒清热解毒。结论气虚血瘀证为AMI的基本证型,痰浊证、阴虚证、阳虚证是重要的证候要素,通过基本证型和单个或多个证候要素的结合,覆盖AMI主要证型。     

溶栓疗法对老年急性心肌梗死患者的疗效和安全性

迄今，关于溶栓疗法对老年患者的疗效和不良反应及副作用还研究很少。本文报告作者关于溶栓疗法对老年急性心肌梗死（AMI）患者的疗效和安全性进行研究的结果。     

急性心肌梗死溶栓治疗的近期临床疗效

目的研究急性心肌梗死（AMI）溶栓治疗的近期临床疗效。方法320例AMI患者中240例进行溶栓治疗，80例未溶栓治疗。分为再通组、未通组、未溶栓组，比较组间近期临床预后的差异。结果再通组近期临床预后明显好于未通组，而未通组与未溶栓组比较，临床预后略好，但差异无显著性。结论溶栓治疗是AMI的首选治疗方法。     

女性急性心肌梗死患者溶栓疗效临床对比研究

急性心肌梗死（AMI）再灌注治疗对于女性AMI患的近期疗效,国内报道较少。本研究旨在探讨静脉溶栓治疗对女性AMI患近期疗效。     

急性心肌梗死扩大溶栓治疗指征的探讨——附102例分析

<正> 我院1991年来收治急性心肌梗死(AMI)102例,97年前严格按照省协作组规定的溶栓入选指征:97年1月以来扩大了溶栓疗法指征.今对两组的入院溶栓比例、死亡率、再梗率、以及溶栓再通率等作一分析探讨.1 资料与方法1.1 研究对象对照组:1991年1月～1996年12月收治的AMI 62例(年龄大于65岁20例),入选溶栓治疗的仅18例.人选指征为①胸痛>30分钟,含服硝酸甘油无效;②二个导联ST抬高(胸导联抬高>0.2mv,肢导联抬高>0.1mv);③距发病时间≤12小时;④年龄≤65岁;⑤血压≤160/100mmHg;⑥无出血倾向等禁忌症.扩大组:1997年1月～1999年6月收治的     

70岁以上急性心肌梗死病人溶栓疗效的临床观察

目的 探讨溶栓治疗对≥70岁AMI病人的临床意义。方法 将所有AMI病人按年龄分为两组,≥70岁组(132例)和<70岁组(156例)。所有病人随机静脉给予尿激酶或rt-PA,观察其血管再通率、出血并发症、病死率及各种合并症。结果≥70岁组静脉溶栓治疗后120min血管再通率为70.5％,<70岁组为74.4％,两组差异无统计学意义(P<0.05);≥70岁组与<70岁组出血并发症分别为28.8％和25％,脑出血为1.5％和0.6％,两组差异无统计学意义(P相似文献   

糖尿病中医治疗临床疗效观察

目的探讨中医辨证分型治疗糖尿病的临床效果及优越性。方法将该院2013年10月—2014年2月收治的180例糖尿病患者,随机平分为观察组和对照组,观察组采用中医辨证分型方法治疗,对照组则采用常规西医方法治疗,将两组患者的治疗效果进行对比。结果观察组采用中医方法治疗,有效率为94.4%,对照组采用常规西医方法治疗,其有效率为72.2%,两组患者总有效率比较,P〈0.05,差异有统计学意义。结论中医辨证分型治疗糖尿病,使治疗更有针对性,可有效改善患者病症,取得良好治疗效果,减轻患者痛苦,与西医治疗相比具有一定优越性。     

急性心肌梗死患者溶栓治疗后胸导QRS波群综合电压对预后的影响

目的 通过对急性前壁、前间壁心肌梗死患者三次心电图QRS波群综合电压(R+S)的观察和比对,探讨急性心肌梗死患者溶栓治疗后胸导QRS波群综合电压对预后的影响.方法 符合溶栓治疗的急性前壁ST段抬高型、前间壁ST段抬高型心肌梗死患者64例,分别测量患者入院后第1次心电图,尿激酶150万U静脉溶栓治疗后半小时至1小时期间心...     

胰岛素联合中医汤剂治疗1.5型糖尿病(LADA)的疗效分析

目的 研究胰岛素联合中医汤剂治疗1.5型糖尿病(LADA)的疗效.方法 2014年3月—2020年5月选择该院收治的78例LADA成年患者.按照随机原则分为对照组及观察组,各39例.对照组采用胰岛素治疗;观察组采用胰岛素及中药汤剂联合治疗.连续治疗3个月后进行指标评价,包括血糖水平(FPG、2 hPG)、空腹血浆C肽水...     

HbA1c水平对急性心肌梗死患者PCI术后心脏功能与MACE发生率及死亡率的影响

目的探讨糖化血红蛋白(HbA1c)水平对行经皮冠状动脉介入治疗(PCI)术急性心肌梗死患者术后心脏功能、主要心血管不良事件(MACE)发生率及死亡率的影响。方法选取我院收治行PCI术急性心肌梗死患者100例,依据术前静脉HbA1c水平分为两组,其中A组患者HbA1c值8%,而B组患者HbA1c值≥8%,每组各50例;比较两组患者术后Killip心功能分级、NYHA心功能分级、左室舒张末期内经(LVDd)水平、左心房大小(LAd)水平、左心室射血分数(LVEF)水平、随访MACE发生率及死亡率。结果 A组患者术后Killip心功能分级水平显著优于B组(P0.05);A组患者术后NYHA心功能分级水平显著优于B组(P0.05);A组患者LVDd、LAd及LVEF水平均显著优于B组(P0.05);A组患者随访MACE总发生率显著低于B组(P0.05);A组患者随访死亡率显著低于B组(P0.05)。结论高HbA1c水平可能影响行PCI术急性心肌梗死患者术后心脏功能恢复,导致MACE和死亡风险上升。     

Differences in patients with acute myocardial infarction treated with primary angioplasty or thrombolytic therapy. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group

BACKGROUND: Little is known about the differences in patients with acute myocardial infarction (AMI) treated with primary angioplasty or intravenous thrombolysis in clinical practice. METHODS: In all, 5,906 patients with AMI were registered by the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) study. Of these, 491 (8.3%) patients were treated with primary angioplasty and 2,817 (47.7%) with intravenous thrombolysis. RESULTS: There were only minor differences in baseline characteristics between the two groups. Prehospital delay time (median) was longer in the angioplasty group than in the thrombolysis group (161 vs. 120, p = 0.001), as was door-to-treatment time (88 vs. 30 min; p = 0.001). Patients treated with primary angioplasty more often had contraindications for thrombolytic therapy (12.9 vs. 6%, p = 0.001) and received beta blockers (65 vs. 58.1%, p = 0.004), heparin (98.2 vs. 91.6%, p = 0.001), angiotensin-converting enzyme (ACE) inhibitors (64.8 vs. 50%, p = 0.001) and "optimal" concomitant medication (56.4 vs. 42.9%, p = 0.001) more often. Univariate analysis showed a significant lower incidence of heart failure (5.3 vs. 16.5%, p = 0.001), postinfarct angina (7.3 vs. 16.4%, p = 0.001), in-hospital death (7.9 vs. 11.7%, p = 0.015) and the combined end point (21.6 vs. 40.3%, p = 0.001) in these patients. Stepwise logistic regression analysis revealed optimal concomitant medication [odds ratio (OR) = 0.94, 95% confidence interval (CI): 0.89-0.98) and the type of revascularization (OR = 0.65, 95% CI: 0.58-0.73) to be associated with a significant reduction in the incidence of the combined end point. Similar results were obtained in all predefined subgroups. CONCLUSIONS: In clinical practice, patients treated with primary angioplasty are more often treated with beta blockers and ACE inhibitors than patients treated with intravenous thrombolysis. Thus, the selection of patients and the type of revascularization contributes to the reduction in mortality, overt heart failure, and postinfarct angina in these patients.     

Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)

ObjectivesThis study sought to investigate the effect of treatment delay on microvascular reperfusion in ST-segment elevation myocardial infarction (STEMI) patients from the large, multicenter, prospective HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial.BackgroundDespite restoration of epicardial blood flow during primary percutaneous coronary intervention (PCI), one-third of patients do not obtain myocardial perfusion due to impairment in the microvascular circulation.MethodsWe examined the effect of symptom onset-to-balloon time (SBT) and door-to-balloon time (DBT) on myocardial reperfusion during primary PCI in STEMI, utilizing resolution of ST-segment elevation (STR) and the myocardial blush grade (MBG). The primary analysis was the relationships between SBT ≤2, >2 to 4, and >4 h and DBT ≤1, >1 to 1.5, >1.5 to 2, and >2 h with MBG and STR. Clinical risk was assessed using a modified version of the Thrombolysis In Myocardial Infarction risk score for STEMI.ResultsIn 2,056 patients, absent microvascular perfusion (MBG 0/1) and STR (STR <30%) after primary PCI was significantly more common in patients with longer SBT, in patients with both low and high clinical risk profiles. By multivariable analysis, SBT (p < 0.0001), anterior infarction (p < 0.0001), reference vessel diameter (p = 0.005), lesion minimum lumen diameter (p < 0.0001), hyperlipidemia (p = 0.03), and current smoking (p = 0.001) were independent predictors of MBG 0/1, whereas SBT (p = 0.007), anterior infarction (p < 0.0001), and history of renal insufficiency (p = 0.0002) were independent predictors of absent STR. DBT (p < 0.0001) was an independent predictor of MBG 0/1. MBG 0/1 and STR<30% identified patients with increased 3-year mortality.ConclusionsThe present study suggests that delay in mechanical reperfusion therapy during STEMI is associated with greater injury to the microcirculation.     

Effect of Coronary Thrombolysis on the Plasma Concentration of Osteonectin (SPARC, BM40) in Patients with Acute Myocardial Infarction

Osteonectin is a phosphoglycoprotein exclusively located in bone and platelet -granules. Human platelet-derived osteonectin is released into plasma after thrombin-induced activation. Recognizing the unique distribution of the osteonectin pool, we first sought to investigate whether osteonectin could serve as a sensitive marker of platelet activity, and identify patients with acute myocardial infarction (AMI). The second objective was to define the effects of thrombolytic therapy in these patients on the plasma concentrations of osteonectin at prespecified time points following attempted reperfusion. Osteonectin levels by ELISA were determined in AMI patients before thrombolysis and at 3, 6, 12, and 24 hours thereafter and compared with 12 healthy controls. At baseline, soluble osteonectin plasma levels were similar between controls (447.7±20.6ng/ml) and AMI patients (425.7±43.3ng/mL; p=NS). A significant increase of the soluble osteonectin was observed at 3 hours after thrombolysis (519.4±26.9ng/mL; p=0.03), and was followed by a decrease to baseline levels at 6 hours after attempted reperfusion. Contrary to expectations, the plasma osteonectin level in our pilot study was not a sensitive marker distinguishing patients with AMI. The early peak of soluble osteonectin at 3 hours after thrombolytic therapy is most likely not related to coronary thrombolysis per se but rather to the phasic changes of platelet activity during myocardial ischemia-reperfusion. The unquestionable platelet origin of this protein and the lack of elevated plasma levels of this -granule constituent, challenge the postulate of uniform platelet activation in AMI patients.     

Effect of Intravascular Cooling on Microvascular Obstruction (MVO) in Conscious Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: Results from the COOL AMI EU Pilot Study

ObjectiveCOOL AMI EU pilot was a multi-center, randomized controlled trial to assess feasibility and safety of rapid intravascular therapeutic hypothermia (TH) in conscious patients with anterior ST-elevation myocardial infarction (STEMI) undergoing primary PCI (PPCI). We report the effect of hypothermia upon microvascular obstruction (MVO).MethodsConscious patients with anterior STEMI and symptom duration <6 h were recruited and randomized to PPCI + TH or PPCI alone. TH was induced using the ZOLL® Proteus™ intravascular temperature management system and rapid infusion of 1 L of cold normal saline, with a target temperature of 32 °C. MVO was measured by cardiac magnetic resonance (CMR) at 4 to 6 days post-MI. MVO larger than 3.9% of LV was considered as extensive MVO.Results50 patients were randomized; mean age was 58 years, and 86% were men. At reperfusion, mean intravascular temperature for the TH group was 33.6 ± 1 °C. The presence of MVO was high and not different in both groups (74% vs. 77%, p = 0.79). The proportion of patients with extensive MVO was 11% in the TH group and 23% in the control group (OR 0.4 95%CI 0.07–2.35, p = 0.30). Patients with extensive MVO showed reduced EF at 4–6 days (34% versus 43%, p = 0.01). The percentage of patients with EF <35% at 30 days was 6% in the TH group versus 24% in the control group (p = 0.19).ConclusionIn the COOL-AMI Pilot Trial, the presence of MVO in both test groups was high and extensive MVO was related with reduced LVEF. The efficacy of therapeutic hypothermia (TH) in MVO reduction should be tested in a pivotal trial.